Yellow Fever Vaccine Market Report 2026

The yellow fever vaccine market size has grown steadily in recent years. It will grow from $4.74 billion in 2025 to $4.97 billion in 2026 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to recurring yellow fever outbreaks, government immunization mandates, established vaccine efficacy, international travel requirements, public health initiatives.

The yellow fever vaccine market size is expected to see steady growth in the next few years. It will grow to $5.88 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to climate-driven mosquito spread, increasing global travel, expansion of vaccination infrastructure, higher funding for disease prevention, stronger outbreak preparedness. Major trends in the forecast period include expansion of routine immunization programs, rising demand from international travelers, increased government-led vaccination campaigns, growing use of single-dose vaccines, focus on endemic disease prevention.

The growth of international travel is expected to drive the expansion of the yellow fever vaccine market in the coming years. International travel involves the movement of people across national borders for purposes such as tourism, business, or personal reasons. This trend is increasing due to rising global mobility, supported by economic recovery and the easing of post-pandemic travel restrictions. The yellow fever vaccine market caters to travelers by offering mandatory or recommended immunization for entry into areas where yellow fever is prevalent. For example, in January 2024, the World Tourism Organization (UNWTO) reported that a Spain-based international tourism agency recorded 1.286 billion global international tourist arrivals in 2023, up from 0.96 billion in 2022, marking a year-on-year increase of 0.326 billion international tourists. Consequently, the rise in international travel is contributing to the growth of the yellow fever vaccine market.

Major companies in the yellow fever vaccine market are increasingly emphasizing the development of innovative solutions, such as T-cell adaptive booster vaccines, to enhance long-term immunity, improve vaccine effectiveness, and overcome the limitations of conventional live-attenuated vaccines. T-cell adaptive booster vaccines are designed to bolster the immune system by specifically stimulating T-cell responses, enabling the body to recognize and combat infections more efficiently compared to traditional antibody-centered vaccines. For example, in April 2025, the All India Institute of Medical Sciences, a healthcare institute based in India, launched Yellow Fever Vaccination to provide travelers with protection against the mosquito-borne viral disease and to issue the internationally recognized vaccination certificate. This initiative aims to improve vaccine accessibility within Telangana, minimizing the need for long-distance travel to other authorized centers. Furthermore, the program ensures compliance with international health regulations by offering safe administration under medical supervision, particularly for individuals with contraindications.

In November 2025, Mabloc, LLC, a biotechnology company based in the US, collaborated with Instituto Butantan to advance a first-in-class monoclonal antibody therapy for the treatment and prevention of yellow fever. This collaboration aims to develop a safe and effective post-exposure and preventive therapy for yellow fever, addressing the unmet medical need for disease-specific treatment. Instituto Butantan is a public research center and vaccine manufacturer based in Brazil.

Major companies operating in the yellow fever vaccine market are Sanofi S.A., Bio-Manguinhos, Institut Pasteur de Dakar, Instituto Butantan, Bio Farma, Biological E. Limited, Beijing Tiantan Biological Products Co. Ltd., Wuhan Institute of Biological Products, Merck & Co. Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Lonza Group AG, WuXi Biologics, Ology Bioservices, Valneva SE, Bavarian Nordic A/S, Panacea Biotec Ltd., Biovac, Novavax Inc., PnuVax Incorporated.

North America was the largest region in the yellow fever vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the yellow fever vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the yellow fever vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the yellow fever vaccine market by increasing the cost of imported vaccine antigens, cold chain equipment, and sterile packaging materials. These impacts are most pronounced in both powder based and liquid vaccine formulations, particularly in developing regions that rely on external suppliers. Rising tariff related expenses have placed additional strain on public immunization budgets and government procurement programs. In some cases, this has contributed to delayed tenders and constrained vaccine availability. However, tariffs are encouraging regional vaccine manufacturing capabilities, technology transfer initiatives, and more resilient local supply chains over the long term.

The yellow fever vaccine market research report is one of a series of new reports that provides yellow fever vaccine market statistics, including yellow fever vaccine industry global market size, regional shares, competitors with a yellow fever vaccine market share, detailed yellow fever vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the yellow fever vaccine industry. This yellow fever vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The yellow fever vaccine is a live, weakened viral vaccine designed to prevent yellow fever, a severe viral disease spread by mosquitoes. It is usually given as a single dose and offers long-term immunity, often for life. The vaccine is particularly crucial for individuals residing in or traveling to regions where the disease is common.

The primary forms of the yellow fever vaccine are powder and liquid. The yellow fever vaccine powder is a lyophilized (freeze-dried) version of the vaccine, which must be reconstituted with a specific diluent prior to administration to confer immunity against the yellow fever virus. This includes various treatment types, such as pain management medications and oral rehydration. The vaccine is utilized in routine immunization, for travelers, and other purposes, and is administered by several end users, mainly hospitals, diagnostic centers, point-of-care centers, and others.

The yellow fever vaccine market consists of sales of vaccine syringes, needles, and vaccine storage equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.